Factify replaces static PDFs with authoritative, intelligent records that allow AI to take charge of business documents.

TEL AVIV, Israel, Jan. 28, 2026 — Factify, creators of the post-PDF document standard, today announced a $73M seed round to build a new foundation for documents. The round was led by Valley Capital Partners, with participation from technology and business leaders including John Giannandrea, former Head of AI at Google and SVP of AI at Apple, Ken Moelis, Founder of investment bank Moelis & Co., and Peter Brown, CEO of renowned quantitative hedge fund Renaissance Technologies.

More than 30 years after Adobe introduced the PDF, it remains the default format for business records, contracts, agreements, and compliance documents, with an estimated three trillion PDFs in circulation worldwide. Yet the core document technology itself has barely evolved: Today’s documents provide no native way to identify the latest authoritative version, who accessed it, or whether the information inside can be trusted. As organizations increasingly rely on AI to review, approve, and act on documents, they are forcing those systems to operate on disconnected, static files that lack identity, provenance, connectivity, and governance.

Factify was built to rebuild the digital document itself – for the first time since the PDF was created in the early 1990s. The Factified document is a governed record, with built-in control, authenticity, and intelligence. It can be created, used, and trusted equally by humans and machines.

“Replacing the PDF is a once-in-a-generation opportunity,” said Matan Gavish, Founder and CEO of Factify. “We don’t just want to solve the inadequacies of the PDF – we want to do it in a way that creates a bedrock for post-AI businesses. PDFs remain the last major holdout of the pre-digital world inside document-heavy organizations. Layering outdated tools like digital signatures on top of static files only makes companies less future-proof, especially as AI moves into core business workflows. Forward-looking companies want software investments that compound over time. What’s missing is a new foundation that enables compounding software and AI investments in regulated industries. That’s what Factify is building.”

In 2012at Stanford University Gavish began publishing research with Professor David Donoho, a recipient of the MacArthur, Shaw, and Gauss prizes, that included early warnings about the limitations of PDFs in an increasingly automated world. He later joined the faculty of the Hebrew University of Jerusalem as a computer science professor, but continued his document obsession. He founded Factify in late 2023.

Factify is Document-as-Infrastructure. Every Factified Document carries its own identity, access rules, version history, and intelligence. It records every meaningful event in a permanent audit log and enforces governance directly within the document. Workflows that today require external tools, such as approvals, signatures, redaction, expiration, and compliance checks, happen natively inside the document itself.

Because Factified documents are machine-readable and uniquely addressable, they remain continuously available as a verifiable source of truth for both people and AI systems. Instead of copying files across inboxes, drives, and platforms, organizations maintain a single authoritative document that retains its identity, audit trail, and purpose wherever and whenever it is used.

“What drew us to Factify is that this is not a feature or a productivity layer,” said Steve O’Hara, Founder and Managing Partner at Valley Capital Partners. “It is a fundamental rethinking of what a document is at a time when AI is starting to act on business information. The team is building a new default for trust, governance, and automation, and that kind of foundation only comes along once every few decades.”

Factify is initially focused on regulated, document-heavy sectors such as banking, insurance, legal services, human resources, and operations, where the cost of ambiguity is highest. Legal teams use Factify documents to enforce NDAs before access is granted, limit visibility to specific sections, and prove which version is authoritative. Operations teams run vendor onboarding and approval processes directly inside documents, replacing fragmented workflows spread across email threads, shared folders, and disconnected tools. Early adopters report that as more documents are Factified, they are better prepared to introduce AI automation in a safe and controlled way.

The capital will be used to expand the engineering team, deepen the core platform, and work closely with early enterprise partners in highly regulated industries. The company is also expanding its U.S. presence, including plans to establish Pittsburgh as a major hub for customer engagement and operations, reflecting its focus on enterprise adoption and long-term stability.

“Factify is fundamentally changing the way the world does business and Pittsburgh is proud to welcome them to our community,” said Pittsburgh Mayor Corey O’Connor. “Our region has a history of innovation and opportunities for next generation technology companies like Factify, who are revolutionizing documents. Bringing cutting-edge companies like Factify to Pittsburgh helps develop our workforce and tap into homegrown talent that will continue to lead the world’s digital evolution.”

“We’re excited to welcome Factify to the United States and Pittsburgh. Having a global company choose to locate in our region where technology meets innovation speaks volumes to the eco-system that we have created here,” said Stefani Pashman, CEO of the Allegheny Conference on Community Development. “The Pittsburgh region is not just a place where companies are launched but is also a place where companies come to build core systems and technologies.”

Media Contact

Lazer Cohen
[email protected] 
347-753-8256

SOURCE Factify

Chicago-based platform replaces legacy TMS systems with unified AI agents and financial workflows, delivering triple digit year-over-year growth

CHICAGO, Jan. 28, 2026 — Datatruck, the AI-native operating system for North American long-haul carriers, today announced a $12 million Series A round led by Avenue Growth Partners (“Avenue”), with participation from existing investors. The capital positions Datatruck to accelerate product development and extend its technological lead as carriers increasingly replace legacy transportation management systems with modern, AI-driven platforms.

Datatruck is purpose-built for long-haul carriers that have outgrown legacy TMS software and fragmented point solutions. The platform serves as a system of record for dispatch, load management, and compliance, while embedding AI agents and financial workflows directly into day-to-day operations. With 150+ integrations connecting seamlessly to dispatch, fuel cards, factoring, and compliance tools, Datatruck delivers an all-in-one transportation system that helps carriers run more efficiently, maintain control at scale, and make better decisions across the business.

The platform’s financial management capabilities, including real-time profitability tracking, automated IFTA reporting, and integrated factoring through FinTruck, give carriers visibility into unit economics that legacy systems can’t provide. This operational intelligence, powered by AI agents that automate routine tasks and surface critical insights, is driving carrier adoption and retention.

“Long-haul carriers don’t need more disconnected tools, they need an operating system that can scale with their business,” said Shah Rahmanov, CEO and Co-Founder of Datatruck. “Datatruck was built to replace legacy systems with an AI-native platform that integrates operations, automation, and financial workflows in one place. That’s what modern carriers expect, and it’s why we’re seeing accelerating adoption.”

Carriers are increasingly choosing Datatruck as they move away from legacy platforms that struggle to support growing operational complexity. Datatruck has already replaced hundreds of competitive and legacy TMS systems as carriers modernize their core operating infrastructure, helping them reconcile financial data, prevent revenue leakage, and ensure money isn’t left on the table.

“We switched to Datatruck from a legacy TMS because it couldn’t keep up with our operation,” said Stefan Trifan, President of APL Cargo. “Datatruck puts carrier profitability front and center in the platform, which helps my team operate more efficiently and continuously expand our margins.”

Avenue’s investment reflects conviction in Datatruck‘s customer momentum and differentiated approach to applying AI inside mission-critical trucking workflows.

“Datatruck stood out to us because customers are already using its AI agents to drive real operational efficiency, not just experimenting with them,” said Ryan Russell, Founding Partner at Avenue. “This is an AI-native platform taking share in a market that’s ready to move beyond legacy systems, and we’re excited to partner with the team as they scale.”

The new capital will be used to deepen Datatruck‘s AI capabilities, expand its product and customer-facing teams, and continue scaling across the North American long-haul carrier market.

About Datatruck

Datatruck is an AI-native operating system for North American long-haul trucking carriers. The platform combines transportation management, embedded financial workflows, and AI agents into a single system of record designed to replace legacy TMS platforms. Datatruck serves approximately 500 carriers across the United States and is headquartered in the Chicago area.
Learn more at www.datatruck.io.

About Avenue Growth Partners

Avenue Growth Partners is an early growth equity firm backing exceptional founders building category-defining vertical technology companies. The firm partners closely with management teams to help scale durable, category-winning businesses.
Learn more at www.avenuegp.com.

Media Contact:
Ludington Media on behalf of Datatruck
[email protected]
New York, NY
551 795 5950

SOURCE Datatruck

Enabling Direct Therapeutic Access Beyond the Blood-Brain Barrier 

BALTIMORE, Jan. 28, 2026 — CraniUS Therapeutics LLC, a privately held neurotechnology company, today announced it has raised $20 million in Series B financing to accelerate development of NeuroPASS™, a fully implantable, skull-embedded platform designed to bypass the blood-brain barrier (BBB) and enable targeted drug delivery and monitoring in the brain.

NeuroPASS™ is being developed as a multi-product platform, with an initial roadmap of three complementary products intended to progressively expand therapeutic capability. Together, these devices are intended to evolve cranial implants from passive reconstructive hardware into an active therapeutic interface capable of supporting long-term outpatient care.

CraniUS Therapeutics was founded by Dr. Chad Gordon, a Johns Hopkins neuroplastic surgeon and pioneer of the new surgical field known as Neuroplastic Surgery, who has spent more than 15 years studying and investigating the temporal cranial space as an optimal site for therapeutic delivery. The company was born from a persistent clinical challenge Dr. Gordon encountered in practice: patients with devastating neurological diseases often succumbed not because surgery could not help, but because life-saving medicinal therapies could not reach the brain due to the BBB.

“This is not an incremental advance—it represents a fundamentally new approach to treating neurological disease and brain cancer,” said Dr. Gordon, Founder and Executive Chair of CraniUS Therapeutics. “We set out to build a platform that could help address a therapeutic barrier that has limited care for decades.”

The Series B financing follows CraniUS’s $20 million Series A round in 2022. The Series B includes $19 million from private investors and $1 million in non-dilutive funding from the State of Maryland, bringing total capital raised to approximately $40 million. The new capital is expected to support operations into 2027 and will support regulatory submissions, manufacturing scale-up and product testing towards future commercialization.

CraniUS holds 15 issued domestic patents supporting its platform and long-term product roadmap, as well as numerous international patents.

“Having led large academic health systems and worked at the intersection of care delivery and innovation, we’ve put robots in operating rooms and AI in radiology suites, but the blood-brain barrier has stubbornly ignored a century of pharmaceutical and medical device innovation, said Dr. Stephen Klasko, a member of the CraniUS board of directors.” “NeuroPASS represents exactly the kind of ‘why not?’ thinking that transforms medicine, not incremental improvement, but a fundamental reimagining of how we access the brain.”

About CraniUS Therapeutics CraniUS Therapeutics is a neurotechnology company developing the first fully implantable platform to bypass the blood-brain barrier for long-term, programmable drug delivery. Its flagship device, NeuroPASS™, is designed to transform the treatment landscape for debilitating neurological conditions across multiple disease types by leveraging the temporal skull space. CraniUS Therapeutics is headquartered in Baltimore, Maryland, and collaborates globally with industry leading experts in neurosurgery, drug delivery, implant design, device engineering, and manufacturing.

Important Regulatory Notice
NeuroPASS™ is an investigational device and has not been approved or cleared by the U.S. Food and Drug Administration for clinical use. All described uses are under development and subject to regulatory review.

Media Contact:
Elizabeth Dale
Executive Advisor, Strategic Partnerships & External Relations
[email protected]
www.craniusmed.com

SOURCE CraniUS Therapeutics

Des capitaux d’investissement pour permettre la réalisation des produits et leur mise sur le marché

BELLEVUE, Washington, 28 janvier 2026 — Lassen Peak a annoncé aujourd’hui la conclusion de financements par emprunt et par actions, pour un total de plus de 10 000 000 $. Les financements ont été menés par Structural Capital, une société de capital-risque et de crédit privé axée sur la croissance située à Menlo Park, en Californie. En plus du financement par emprunt à risque par Structural Capital, les actionnaires existants ont mis à disposition des capitaux supplémentaires pour contribuer à l’introduction par la société du premier système radar portatif entièrement intégré au monde pour la détection d’armes dissimulées. Outre Structural Capital, les principaux investisseurs sont AI Capital Partners, Lauder Partners, LionCrest Ventures, Madrona Ventures, Octave Ventures, et d’autres investisseurs stratégiques, tels qu’Axon Enterprises, un leader mondial des technologies de sécurité publique.

Lassen Peak est pionnier dans l’introduction de la technologie radar d’imagerie à ondes térahertz submillimétriques dans le premier système radar portable au monde pour la détection d’armes dissimulées, qui peut être utilisé n’importe où sur le terrain par les forces de l’ordre, l’armée et les services de sécurité dans les lieux privés. Répondant l’une des plus grandes menaces pour les forces de l’ordre dans leur mission de sécurité publique, les fouilles corporelles d’armes ou « fouilles par palpation » sont extrêmement dangereuses pour les personnes qui les effectuent, ainsi que pour celles qui sont fouillées. En raison de la proximité physique et de la nature litigieuse du contact physique, la menace grave que constituent les armes dissimulées crée une interaction chargée en émotions, que les armes existent ou non – ce scénario tendu et la fouille par palpation invasive peuvent conduire à une escalade dangereuse de l’usage de la force qui peut entraîner des blessures graves ou la mort.

Kai Tse, cofondateur et associé gérant de Structural Capital, a déclaré : « Lassen Peak renferme les éléments d’une société licorne potentielle, capable de définir une nouvelle catégorie importante de produits sur les marchés des forces de l’ordre, de l’armée et du secteur privé, dans le monde entier. Nous sommes ravis de soutenir la croissance et l’expansion de l’entreprise ».

Hatch Graham, PDG et président du conseil d’administration de Lassen Peak, a ajouté : « Nous nous réjouissons des solutions de capital sur mesure proposées par l’équipe de Structural Capital et, avec le soutien collectif des investisseurs existants, nous sommes impatients de réaliser le produit de charte de Lassen Peak et de concrétiser notre vision, qui est de réduire l’usage de la force tout en augmentant la confiance et la sécurité dans les applications de sécurité publique ».

À propos de Lassen Peak

Lassen Peak est une startup de la région de Seattle caractérisée par un mélange unique de leaders technologiques dans les domaines du sans-fil à très haut débit, de l’imagerie radar, de l’intelligence artificielle, de la géolocalisation et d’autres technologies. En associant les technologies de pointe à la nécessité de transformer les solutions de sécurité publique sur le terrain, l’équipe s’emploie à fournir aux forces de l’ordre et à la société des alternatives sûres et moins controversées aux anciennes méthodes d’identification des objets dangereux et des armes dissimulées.

Lassen Peak a réuni des conseillers et des membres de comités très divers qui ont occupé des postes clés dans les principales organisations américaines de maintien de l’ordre et de défense des droits civils, notamment en tant que conseiller général de l’ACLU, président de la National Organization of Black Law Enforcement Executives, CIO du gouvernement des États-Unis, commandant du LAPD, directeur exécutif du Congressional Black Caucus, présidente de la National Association of Women Law Enforcement Executives, membre du conseil d’administration de la National Association of Civilian Oversight of Law Enforcement, et bien d’autres encore.

http://www.lassenpeak.com

Logo – https://mma.prnewswire.com/media/1686113/lassen_peak_Logo.jpg

LYONS, Colo., Jan. 28, 2026 — Elysium Therapeutics, an emerging biopharmaceutical company developing treatments specifically designed to prevent and reverse overdoses caused by highly potent, synthetic opioids especially when ingested orally, today announced that it has completed a $7.5 million SAFE round. Elysium intends to accelerate development of its SOOPR™ (Synthetic Opioid Overdose Protection and Reversal) technology designed specifically as a rescue treatment for overdoses brought on by synthetic opioids, including fentanyl and the emerging threat of more potent nitazenes.

“With these funds in place, we have initiated work to progress our SOOPR technology through preclinical and clinical studies as we develop this important, life-saving technology to address the deadly overdose epidemic caused by illicit synthetic opioids,” said Greg Sturmer, CEO of Elysium Therapeutics. “Our society continues to see far too many overdose fatalities, and we believe that our SOOPR technology has enormous potential to become the new standard for rescue and as a countermeasure as the illicit drug market evolves to progressively more dangerous opioids.”

SOOPR is a rapid-onset, long-acting rescue agent specifically designed to prevent and reverse overdoses from synthetic opioids, including oral fentanyl and nitazenes. SOOPR utilizes a proprietary naloxone prodrug formulation that offers more rapid onset and longer duration of action than current rescue agents (e.g., NARCAN, Kloxxado, Opvee). The technology is designed to rapidly restore respiration, reducing the risk of hypoxic brain injury and death, and provide 12 – 24 hours of effective opioid blockade to minimize the risk of re-narcotization. Further, SOOPR delivers naloxone with a unique, infusion-like pharmacokinetic profile that is ideally suited to reduce the risk of severe withdrawal symptoms commonly associated with nalmefene and high-dose naloxone products. SOOPR is also intended to prevent same-day re-use of opioids and to offer an essential period for family members and healthcare professionals to assist the overdose patient in accessing medically-assisted therapy, which represents their best opportunity for long-term survival.

Data from in vivo proof-of-concept studies of SOOPR demonstrated a more rapid onset of action versus intranasal and intramuscular naloxone and a significantly longer duration of action. This profile is specifically designed to counteract oral fentanyl and nitazene overdoses associated with prolonged exposures that often outlast the short-acting profile of existing rescue agents.

About Elysium Therapeutics  

Elysium is an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral synthetic opioids, including fentanyl and nitazenes. Elysium is working to establish new standards of safety in the opioid industry by developing SMART™ (Safer Medicines Alleviate Risks and Trauma) products, first- and best-in-class medicines that address the limitations and dangers associated with opioids and overdose rescue agents to reduce suffering from opioid-use disorder, opioid overdose, and acute pain. Elysium’s lead technology, SOOPR™ (Synthetic Opioid Overdose Prevention and Reversal), is a fast-onset, long-acting opioid antagonist specifically designed to address oral synthetic opioid overdose. Tens of thousands of unnecessary overdose deaths each year exemplifies the critical shortcomings of currently available rescue agents, including NARCAN and Opvee. In addition, Elysium is also developing oral-overdose protected (O2P™) hydrocodone for the treatment of moderate-to-severe acute pain, having achieved human proof-of-concept demonstrating a significant reduction in hydrocodone exposure in overdose scenarios versus generic hydrocodone. For more information, please visit https://www.elysiumrx.com.

SOURCE Elysium Therapeutics

Investitionskapital als Startbahn für Produktfertigstellung und Markteinführung

BELLEVUE, US-Bundesstaat Washington., 28. Januar 2026 — Lassen Peak gab heute den Abschluss von Fremd- und Eigenkapitalfinanzierungen in Höhe von insgesamt über 10.000.000 US-$ bekannt. Die Finanzierungen wurden von Structural Capital, einer wachstumsorientierten Risikokapital- und Privatkreditfirma aus Menlo Park, Kalifornien, geleitet. Neben der Finanzierung durch Structural Capital stellten die bestehenden Aktionäre zusätzliches Kapital zur Verfügung, um die Einführung des weltweit ersten voll integrierten Handradarsystems zur Detektion versteckter Waffen zu unterstützen. Neben Structural Capital gehörten zu den Investoren AI Capital Partners, Lauder Partners, LionCrest Ventures, Madrona Ventures, Octave Ventures und andere strategische Investoren wie Axon Enterprises, ein weltweit führender Anbieter von Technologien für die öffentliche Sicherheit.

Lassen Peak leistet Pionierarbeit bei der Einführung der bildgebenden Submillimeterwellen-Terahertz-Radartechnologie im weltweit ersten tragbaren Radarsystem für die Detektion versteckter Waffen, das überall vor Ort für den Einsatz bei der Strafverfolgung, beim Militär und bei privaten Sicherheitsanwendungen eingesetzt werden kann. Die körperliche Durchsuchung auf Waffen per Abtastung oder „Pat-down” ist eine der größten Bedrohungen für die Mitarbeiter der Strafverfolgungsbehörden, die für die öffentliche Sicherheit sorgen und die Abtastung durchführen, und für die durchsuchten Personen. Aufgrund der räumlichen Nähe und des strittigen Charakters des physischen Kontakts führt die ernsthafte Bedrohung durch versteckte Waffen zu einer emotional aufgeladenen Interaktion, unabhängig davon, ob Waffen vorhanden sind oder nicht. Diese angespannte Situation und die invasive körperliche Abtastung können zu einer gefährlichen Eskalation der Gewaltanwendung führen, die zu schweren Verletzungen oder zum Tod führen kann.

Kai Tse, Mitbegründer und geschäftsführender Gesellschafter von Structural Capital, erklärt: „Lassen Peak enthält die Elemente eines potenziellen Einhorn-Unternehmens, das in der Lage ist, eine wichtige neue Produktkategorie für die Strafverfolgungsbehörden, das Militär und den privaten Sektor weltweit zu definieren. Wir freuen uns, das Wachstum und die Expansion des Unternehmens unterstützen zu können.”

Der CEO und Vorstandsvorsitzende von Lassen Peak, Hatch Graham, fügt hinzu: „Wir begrüßen die maßgeschneiderten Kapitallösungen, die das Team von Structural Capital anbietet, und freuen uns darauf, mit der kollektiven Unterstützung der bestehenden Investoren das Charta-Produkt von Lassen Peak fertigzustellen und die Vision zu verwirklichen, den Einsatz von Gewalt zu reduzieren und gleichzeitig das Vertrauen und im Bereich der öffentlichen Sicherheit zu erhöhen und Risiken zu senken.”

Informationen zu Lassen Peak

Lassen Peak ist ein Startup-Unternehmen aus Seattle, das eine einzigartige Mischung aus führenden Unternehmen der Branche in den Bereichen Ultrahochgeschwindigkeits-Funkübertragung, bildgebendes Radar, künstliche Intelligenz, Geopositionierung und andere Technologien umfasst. Das Team verbindet fortschrittliche Technologien mit dem Bedarf an neuen Lösungen für die öffentliche Sicherheit vor Ort und setzt sich dafür ein, den Strafverfolgungsbehörden und der Gesellschaft sichere und weniger umstrittene Alternativen zu den herkömmlichen Methoden zur Identifizierung verborgener gefährlicher Gegenstände und Waffen zu bieten.

Lassen Peak hat ein vielfältiges Berater- und Komitee-Team zusammengestellt, das früher Schlüsselpositionen in Amerikas führenden Strafverfolgungs- und Bürgerrechtsorganisationen innehatte, darunter die Rollen des ACLU General Counsel, des President der National Organization of Black Law Enforcement Executives, des CIO der US-Regierung, des LAPD Commanding Officer, des Congressional Black Caucus Executive Director, des President der National Association of Women Law Enforcement Executives, eines Vorstandsmitglieds der National Association of Civilian Oversight of Law Enforcement und andere.

http://www.lassenpeak.com

Logo – https://mma.prnewswire.com/media/1686113/lassen_peak_Logo.jpg

–  Limy’s technology focuses on the fast-growing sector of LLM-powered AI and agentic behavior over user behavior

–  Platform lays the groundwork for AI advertising and agentic commerce

NEW YORK, Jan. 28, 2026 — Limy, the infrastructure platform for optimizing brand performance in the Agentic Web, today emerged from stealth, announcing a $10M funding round led by Flybridge with participation from a16z speedrun. Other investors include Axiom, Clarim, Communitas, JRV & AnD. As the web shifts to AI agents, Limy’s platform provides brands control over visibility, influence, and conversions to drive revenue in the Agentic Web.

Limy is currently working with Fortune 100 companies, with some customers already attributing 10% of their revenues to the platform.

“We’re at the beginning of a seismic shift in how information is organized on the Web, and brands have to adapt to the AI-powered future,” said Jeff Bussgang, General Partner and Co-Founder at Flybridge, Senior Lecturer at Harvard Business School. “Limy is leading the way, turning the black box of AI into a channel for brand discoverability, engagement, and direct revenue. Agentic commerce is the future, and Limy is leading brands there.”

“We’ve been highly impressed with Limy’s distinct approach to AI discoverability, leveraging its proprietary data based on agentic behavior rather than user activity,” said Troy Kirwin, Investment Partner at a16z speedrun. “We’re excited to be backing Limy, who are at the forefront of AI optimization and advertising in our emerging Agentic Web era. We have the utmost confidence in the founding team’s technical prowess and leadership.”

Limy’s technology is uniquely positioned at the intersection of a brand’s web domain and the internet, where data and traffic converge. The platform identifies and decodes every agent and bot interaction that takes place within a site, detecting what information is being fetched and what action is or isn’t being taken. This creates a direct, measurable link between prompts, agent behavior, and business impact. Limy produces its own proprietary data based on these agent interactions, generating specific insights for brands to win AI visibility as the LLM answer. Moreover, by operating directly at the infrastructure web layer, Limy has developed an attribution model based on its distinct ability to track and value the entire customer journey via AI and assign prompts to revenue. Limy is the first platform to connect AI agents to real user outcomes, revealing why, how and what value was generated from AI traffic.

“Other players in this space are focused on what users are entering into LLMs, i.e. user data, but in the Agentic Web, agents’ actions are much more important,” says CEO and co-founder Aviv Shamny. “The shift from user data to agent data is underway—and that’s exactly where we’re focused, giving us a clear advantage. We’re delighted that a16z speedrun, Flybridge and our other tier one investors have recognized how critical this is to the future of AI discovery.”

Limy’s founding team, CEO Aviv Shamny, COO Ido Zabarsky and CTO Ori Reichman, are world-leading data experts who possess an in-depth understanding and technical know-how of how LLMs operate. Both Shamny and Zabarsky are a16z speedrun scouts.

Brands across Ecommerce, retail, media, travel, finance, and B2B SaaS win in the agentic web—marketers can start via Limy’s self-serve dashboard, while enterprises and agencies can gain access to custom deployments with deeper integrations and more powerful features and performance. Get started now at limy.ai or contact [email protected] .

About Limy

Limy empowers brands to control influence and conversions in the Agentic Web—while driving measurable revenue. Focusing on agentic behavior over user behavior, Limy is laying the foundations for the AI advertising network. The company is backed by a16z and Flybridge among other investors, and is led by world-class data experts. Go to limy.ai for more information.

About Flybridge Capital

Flybridge is a leading early-stage venture capital firm backing the builders of an AI-powered future, from developer platforms to agentic applications to transformative ideas that reshape how humans work, create, and connect. With 20+ years backing founders at the seed stage and a portfolio of 200+ companies, we give founders unmatched access to enterprise customers, technical talent, and a founder-first platform that accelerates growth from day one. Portfolio companies include Arcee.ai, Blitzy, Codecademy, FalconX, MongoDB, Noetica, NS1, and Splice.

About a16z speedrun

Speedrun is Andreessen Horowitz’s (a16z) flagship program that invests in new startups across consumer/enterprise AI, bio + healthcare, crypto, fintech, games, infrastructure, and companies building toward American dynamism. Founded in Silicon Valley in 2009, a16z has $90B in assets under management.

Media Contact
Diane Mckaye
Si14 Global Communications

[email protected]

SOURCE Limy

Investment intended to fuel advancement of novel Platelet-derived Regenerative Biologic therapy for Sjogren’s disease dry eye and other ocular surface diseases

WATERTOWN, Mass., Jan. 28, 2026 — Stellular Bio, the pioneer of Platelet-derived Regenerative Biologic (PRB) therapeutics, is pleased to announce the closing of its Series 1 financing round.

Led by Ziff Capital Partners and joined by Cockrell Interests and others, the round will help advance Stellular’s lead candidate, STLR-201, into clinical testing as a treatment for Sjogren’s disease dry eye.

Sjogren’s disease (SjD) is a complex multisystem autoimmune disorder affecting roughly 4 million patients in the United States alone.¹ 75 percent of SjD patients say the eye dryness and irritation that is a hallmark of the disease has a major or moderate impact on their lives². Left untreated, SjD and other severe ocular surface diseases can lead to corneal damage and vision loss.

Derived from platelet-progenitor stem cells, STLR-201 is designed to simultaneously modulate the multiple cell and tissue types that are affected in ocular surface disease. This approach is inspired by a robust body of research³ demonstrating the efficacy of autologous blood products, such as platelet-rich plasma, in treating ocular conditions. These treatments, however, must be manufactured separately for each patient from a sample of their own blood — a process that can be cumbersome, inconsistent, and expensive.

STLR-201 and other PRB therapeutics, on the other hand, have the potential to offer a consistent, scalable, off-the-shelf option with the quality standards of approved medicines.

“PRBs are Goldilocks-like treatments that combine the regenerative potential and inherent polypharmacology of plasma and cell therapies with the reproducibility and economy of scale of traditional biologics,” says Stellular CEO Derek Adams. “We believe they will enable us to offer important new options for a large number of patients with multifaceted conditions like ocular surface disease, chronic wounds, osteoarthritis, and more.”

About Stellular Bio

Stellular Bio is dedicated to expanding the reach of regenerative medicine with its pioneering platelet-derived regenerative biologic (PRB) therapy. PRB harnesses the same regenerative potential that underlies bespoke autologous treatments such as platelet-rich plasma, but in the form of a mass-manufactured therapeutic that is standardized, off-the-shelf, and lower cost, with the potential to reach a broad range of patients. Stellular has demonstrated the efficacy of PRB in animal models and has established scalable manufacturing methods to enable clinical trials and commercial production. Stellular is pursuing initial clinical proof of concept in Sjogren’s disease dry eye and aims to subsequently expand into the broader ocular surface disease market and beyond. For more information, visit stellularbio.com.

1) Sjögren’s Foundation

2) Sjögren’s Foundation Living with Sjögren’s patient survey

3) Avila et al, Br J Opthamol, 2019; Allam, I.Y., Delta Journal of Ophthalmology 2021, 22:251–258; Wróbel-Dudzinska et al.,  J. Clin. Med. 2023, 12, 3126; Sanchez-Avila et al., J. Ocular Pharm. and Ther. 2017

Contact
[email protected]

SOURCE Stellular Bio

Capital de inversión para proporcionar la pista para la finalización del producto y su introducción al mercado

BELLEVUE, Wash., 28 de enero de 2026 — Hoy, Lassen Peak anunció la finalización de financiaciones de deuda y capital, por un total de más de 10.000.000 dólares. Los financiamientos fueron liderados por Structural Capital, una firma de crédito privado y de capital de riesgo enfocada en el crecimiento con sede en Menlo Park, California. Además del financiamiento de deuda de riesgo de Structural Capital, los accionistas existentes aportaron capital adicional para apoyar la introducción del primer sistema de radar portátil totalmente integrado del mundo para la detección de armas ocultas. Además de Structural Capital, entre las firmas de inversión destacadas se encuentran AI Capital Partners, Lauder Partners, LionCrest Ventures, Madrona Ventures, Octave Ventures y otros inversores estratégicos, como Axon Enterprises, líder mundial en tecnologías de seguridad pública.

Lassen Peak es pionera en la introducción de la tecnología de radar de imágenes de ondas submilimétricas de terahercios en el primer sistema de radar portátil del mundo para la detección de armas ocultas, que puede utilizarse en cualquier lugar del terreno para su uso en aplicaciones de seguridad policial, militar y de espacios privados. Al abordar una de las mayores amenazas para el personal policial en su labor de brindar seguridad pública, los cacheos físicos de armas son altamente peligrosos tanto para quienes los realizan como para quienes son registrados. Debido a la proximidad física y la naturaleza conflictiva del contacto físico, la grave amenaza de las armas ocultas crea una interacción con gran carga emocional, independientemente de si existen armas. Esta situación tensa y el cacheo físico invasivo pueden llevar a una peligrosa escalada del uso de la fuerza que puede resultar en lesiones graves o la muerte.

Kai Tse, cofundador y socio director de Structural Capital, afirmó: “Lassen Peak reúne los elementos necesarios para convertirse en una empresa unicornio con potencial de éxito, capaz de definir una nueva e importante categoría de producto en los mercados de las fuerzas del orden, el ejército y el sector privado a nivel mundial. Nos entusiasma apoyar el crecimiento y la expansión de la empresa”.

Hatch Graham, consejero delegado y presidente del consejo de administración de Lassen Peak, añadió: “Agradecemos las soluciones de capital personalizadas que ofrece el equipo de Structural Capital y, con el apoyo colectivo de los inversores existentes, esperamos completar el proyecto de Lassen Peak y hacer realidad la visión de reducir el uso de la fuerza, a la vez que aumentamos la confianza y la seguridad en las aplicaciones de seguridad pública”.

Acerca de Lassen Peak

Lassen Peak es una empresa emergente del área de Seattle que reúne a líderes tecnológicos de la industria en tecnología inalámbrica de ultraalta velocidad, radar de imágenes, inteligencia artificial, geoposicionamiento y otras tecnologías. Al combinar las tecnologías avanzadas con la necesidad de una transformación en las soluciones de seguridad pública sobre el terreno, el equipo se compromete a brindar a las fuerzas del orden y a la sociedad alternativas seguras y menos contenciosas a los métodos tradicionales de identificación de objetos peligrosos y armas ocultas.

Lassen Peak ha reunido un grupo diverso de asesores y líderes de comités que anteriormente ocuparon puestos clave en las principales organizaciones de aplicación de la ley y de derechos civiles de Estados Unidos, incluidos los roles de asesor general de la ACLU, presidente de la Organización Nacional de Ejecutivos Negros de las Fuerzas de Aplicación de la Ley, director de Información del Gobierno de Estados Unidos, comandante del LAPD, director ejecutivo del Caucus Negro del Congreso, presidente de la Asociación Nacional de Mujeres Ejecutivas de las Fuerzas de Aplicación de la Ley, miembro de la Junta de la Asociación Nacional de Supervisión Civil de Aplicación de la Ley y otros.

http://www.lassenpeak.com

Logo – https://mma.prnewswire.com/media/1686113/lassen_peak_Logo.jpg